Quemliclustat clinical trials
Also written AB680.
How each study uses quemliclustat is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the quemliclustat studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
12 studies that test it; most in 2023 (3)
| Year | Studies |
|---|---|
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 1 |
| 2022 | 1 |
| 2023 | 3 |
| 2024 | 3 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 7 · Other 5
Arcus Biosciences, Inc. (6) · Nataliya Uboha (1) · Gilead Sciences (1) · Jonsson Comprehensive Cancer Center (1) · Fred Hutchinson Cancer Center (1) · Gulam Manji (1) · Catherine Spina (1)
Often tested with
Tested in the same studies.
Zimberelimab (3) · Domvanalimab (2) · AB928 (2) · Platinum Doublet (1)
Related medicines
As reviewed, each with the page that says it.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 3
Studies that test quemliclustat.
- Dec 2026Study of Gemcitabine, Cisplatin, AB680 and AB122 During First Line Treatment of Advanced Biliary Tract Cancers (QUIC)Phase 2 · Nataliya Uboha
- Dec 2026Adenosine Signaling Modulation and Immune Checkpoint Inhibition With Hormone Sensitive Oligometastatic Prostate CancerPhase 2 · Catherine Spina
- Apr 2027Combination Therapy in Patients With Localized Pancreatic Ductal AdenocarcinomaPhase 2 · Gulam Manji
Studies
Open first, then newest update. How each study uses quemliclustat is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 12
- Zimberelimab and Quemliclustat in Combination With Chemotherapy for the Treatment of Patients With Borderline Resectable and Locally Advanced Pancreatic AdenocarcinomaRecruitingPhase 1/2Jonsson Comprehensive Cancer CenterNCT05688215Written as Quemliclustat
- Enfortumab Vedotin, Pembrolizumab and Quemliclustat for the Treatment of Unresectable Locally Advanced and Metastatic Urothelial CancerRecruitingPhase 1/2Fred Hutchinson Cancer CenterNCT07667335Written as Quemliclustat
- Combination Therapy in Patients With Localized Pancreatic Ductal AdenocarcinomaRecruitingPhase 2Gulam ManjiNCT06048484Written as Quemliclustat
- Adenosine Signaling Modulation and Immune Checkpoint Inhibition With Hormone Sensitive Oligometastatic Prostate CancerRecruitingPhase 2Catherine SpinaNCT05915442Written as Quemliclustat
- Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal AdenocarcinomaActive, not recruitingPhase 3Arcus Biosciences, Inc.NCT06608927Written as Quemliclustat
- A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract MalignanciesCompletedPhase 2Arcus Biosciences, Inc.NCT05329766Written as Quemliclustat
- A Study to Evaluate the Safety and Tolerability of AB680 in Participants With Gastrointestinal MalignanciesCompletedPhase 1Arcus Biosciences, Inc.NCT04104672Written as AB680
- Study of Gemcitabine, Cisplatin, AB680 and AB122 During First Line Treatment of Advanced Biliary Tract Cancers (QUIC)Active, not recruitingPhase 2Nataliya UbohaNCT06048133Written as Quemliclustat
- Study With Various Immunotherapy Treatments in Participants With Lung CancerActive, not recruitingPhase 2Gilead SciencesNCT05676931Written as Quemliclustat
- Metabolism, Excretion, and Mass Balance Study of Quemliclustat in Healthy Adult Participants (ARC-24)CompletedPhase 1Arcus Biosciences, Inc.NCT07364214Written as Quemliclustat
- A Study to Investigate the Safety of AB680 in Healthy VolunteersCompletedPhase 1Arcus Biosciences, Inc.NCT03677973Written as AB680
- A Study to Investigate the Pharmacokinetic Profile of Oral AB680 in Healthy VolunteersCompletedPhase 1Arcus Biosciences, Inc.NCT04575311Written as AB680
Given beside what is tested · 2 — quemliclustat is usual care or a partner of the new treatment
- An Open Label Study Evaluating the Efficacy and Safety of Etrumadenant (AB928) Based Treatment Combinations in Participants With Metastatic Colorectal Cancer.CompletedPhase 1/2Arcus Biosciences, Inc.NCT04660812Written as AB680
- Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate CancerCompletedPhase 1/2Arcus Biosciences, Inc.NCT04381832Written as Quemliclustat
Codes
What other systems call quemliclustat · ClinicalTrials.gg INT001984
- MeSH (NLM) C000723779quemliclustatConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) J6K8WSV73AQUEMLICLUSTATConfirmed FDA, NLM
- NCI Thesaurus C167156QuemliclustatOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000723779 | quemliclustat | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | J6K8WSV73A | QUEMLICLUSTAT | Confirmed FDA, NLM |
| NCI Thesaurus | C167156 | Quemliclustat | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.